Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 3/20 | 0.33 |
| ▸ | MGMT | P16455 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22657962 | 1.00 | CRBN (0.33) | CRBNMGMTGAA | |
| SCHEMBL29444978 | 1.00 | CRBN (0.33) | CRBNMGMTGAA | |
| SCHEMBL29521618 | 1.00 | CRBN (0.33) | CRBNMGMTGAA | |
| SCHEMBL17319197 | 1.00 | CRBN (0.33) | CRBNMGMTGAA | |
| SCHEMBL19725973 | 1.00 | CRBN (0.33) | CRBNMGMTGAA | |
| SCHEMBL23194379 | 1.00 | CRBN (0.33) | CRBNMGMTGAA | |
| SCHEMBL14981499 | 1.00 | CRBN (0.33) | CRBNMGMTGAA | |
| SCHEMBL16329452 | 1.00 | CRBN (0.33) | CRBNMGMTGAA | |
| SCHEMBL16329449 | 0.99 | GAA (0.33) | CRBNMGMTGAA | |
| SCHEMBL26846799 | 0.93 | CRBN (0.36) | CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250114441-A1 | POLYMERIC VACCINE FOR OPIOID ADDICTION | THE JOHNS HOPKINS UNVERSITY | 2025-04-10 | — | — | US | disclosed |
| US-20240238422-A1 | Hypoimmunogenic Biotherapeutics | ADAXION THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240238422-A1 | Hypoimmunogenic Biotherapeutics | ADAXION THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-11819531-B2 | Multifunctional zwitterionic polymer conjugates | KODIAK SCIENCES INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-11819531-B2 | Multifunctional zwitterionic polymer conjugates | KODIAK SCIENCES INC. (US) | 2023-11-21 | — | — | US | disclosed |
| EP-4274582-A1 | HYPOIMMUNOGENIC BIOTHERAPEUTICS | Osprey Biopharmaceuticals, Inc. (US) | 2023-11-15 | — | — | EP | disclosed |
| EP-3659591-B1 | MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES | KODIAK SCIENCES INC (US) | 2023-10-25 | — | — | EP | disclosed |
| US-11779663-B2 | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-10-10 | — | — | US | disclosed |
| US-11779663-B2 | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-10-10 | — | — | US | disclosed |
| CN-116744944-A | Low-immunogenicity biotherapeutic medicine | 奥斯普瑞生物制药有限公司 | 2023-09-12 | — | — | CN | disclosed |
| US-20170002013-A1 | SUBSTITUTED 4-METHYL-PYRROLO[1,2-A]PYRIMIDINE-8-CARBOXAMIDE COMPOUNDS AND USES THEREOF FOR MODULATING GLUCOCEREBROSIDASE ACTIVITY | NORTHWESTERN UNIVERSITY (US) | 2017-01-05 | — | — | US | disclosed |
| US-20160287715-A1 | MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES | KODIAK SCIENCES INC (US) | 2016-10-06 | — | — | US | disclosed |
| US-20160287715-A1 | MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES | KODIAK SCIENCES INC (US) | 2016-10-06 | — | — | US | disclosed |
| WO-2015179823-A2 | LUNG LOCALIZED INHIBITORS OF ALPHA(V)BETA 6 | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2015-11-26 | — | — | WO | disclosed |
| US-8734846-B2 | Methods for the preparation of targeting agent functionalized diblock copolymers for use in fabrication of therapeutic targeted nanoparticles | BIND BIOSCIENCES, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-20130115192-A1 | Methods for the Preparation of Targeting Agent Functionalized Diblock Copolymers for Use in Fabrication of Therapeutic Targeted Nanoparticles | BIND BIOSCIENCES, INC (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130045522-A1 | MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES | OLIGASIS (US) | 2013-02-21 | — | — | US | disclosed |
| US-20130045522-A1 | MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES | OLIGASIS (US) | 2013-02-21 | — | — | US | disclosed |
| WO-2011075736-A1 | MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES | OLIGASIS (US) | 2011-06-23 | — | — | WO | disclosed |
| US-20100104645-A1 | METHODS FOR THE PREPARATION OF TARGETING AGENT FUNCTIONALIZED DIBLOCK COPOLYMERS FOR USE IN FABRICATION OF THERAPEUTIC TARGETED NANOPARTICLES | BIND BIOSCIENCES, INC. (US) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160287715-A1 | MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES | PHOSPHO1, MSN, ZW10 | CRBN 1913/4885MGMT 1221/4885GAA 1525/4885 |
| US-20130115192-A1 | Methods for the Preparation of Targeting Agent Functionalized Diblock Copolymers for Use in Fabrication of Therapeutic Targeted Nanoparticles | GNE, PAM, EPHA2 | CRBN 299/4885MGMT 383/4885GAA 271/4885 |
| US-20170002013-A1 | SUBSTITUTED 4-METHYL-PYRROLO[1,2-A]PYRIMIDINE-8-CARBOXAMIDE COMPOUNDS AND USES THEREOF FOR MODULATING GLUCOCEREBROSIDASE ACTIVITY | GBA1, GBA2, GBA3 | CRBN 3586/4885MGMT 3550/4885GAA 5/4885 |
| US-20250114441-A1 | POLYMERIC VACCINE FOR OPIOID ADDICTION | OPRM1, OPRK1, OPRL1 | CRBN 3368/4885MGMT 3249/4885GAA 2425/4885 |
| US-11779663-B2 | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof | SLC25A1, GCDH, FH | CRBN 3796/4885MGMT 820/4885GAA 2416/4885 |
| US-11819531-B2 | Multifunctional zwitterionic polymer conjugates | PHOSPHO1, MSN, ZW10 | CRBN 1913/4885MGMT 1221/4885GAA 1525/4885 |
| US-20100104645-A1 | METHODS FOR THE PREPARATION OF TARGETING AGENT FUNCTIONALIZED DIBLOCK COPOLYMERS FOR USE IN FABRICATION OF THERAPEUTIC TARGETED NANOPARTICLES | GNE, EPHA2, PAM | CRBN 839/4885MGMT 1047/4885GAA 96/4885 |
| US-20240238422-A1 | Hypoimmunogenic Biotherapeutics | FCGR3B, CD47, IL2 | CRBN 642/4885MGMT 3238/4885GAA 1416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.